GSK Sues Moderna Over Alleged Patent Infringement on mRNA Technologies in Vaccines

GlaxoSmithKline (GSK) has initiated legal action against Moderna, claiming that the mRNA technology employed in Moderna’s COVID-19 vaccine, as well as their respiratory syncytial virus (RSV) vaccine, infringes on patents owned by GSK. The lawsuits have been filed in Delaware, centering around the assertion that the foundational mRNA technology utilized in these vaccines was initially discovered by researchers whose inventions are patented under GSK’s portfolio. Moderna, widely recognized for its innovative use of mRNA technology in vaccine development, now faces the challenge of defending its patent positioning against GSK’s claims. Further details on the ongoing legal proceedings and the specific patents involved can be accessed via Law360.